Given all the commercial-oriented hiring now, I wonder if RVNC has received any hint from the FDA that they might be able to submit the RT002 BLA in glabellar lines partway through the open-label safety study (https://www.clinicaltrials.gov/ct2/show/NCT03004248 )—instead of waiting for the safety study to follow every patient for 12 months.
If so, RVNC could launch RT002 in late 2019 instead of 2020.
Doesn't it seem more reasonable from an expense standpoint to hire the leaders of the commercial team 18 months prior to launch rather than two years prior to launch?
Market Data 
Markets 
AI
